Alexa A Lopez1, Marzena Hiler1, Sarah Maloney1, Thomas Eissenberg1, Alison B Breland2. 1. Virginia Commonwealth University, Department of Psychology and Center for the Study of Tobacco Products, Box 980205, Richmond, VA 23298-0205, USA. 2. Virginia Commonwealth University, Department of Psychology and Center for the Study of Tobacco Products, Box 980205, Richmond, VA 23298-0205, USA. Electronic address: abbrelan@vcu.edu.
Abstract
BACKGROUND: Novel tobacco products entering the US market include electronic cigarettes (ECIGs) and products advertised to "heat, not burn" tobacco. There is a growing literature regarding the acute effects of ECIGs. Less is known about "heat, not burn" products. This study's purpose was to expand existing clinical laboratory methods to examine, in cigarette smokers, the acute effects of a "heat, not burn" "loose-leaf tobacco vaporizer" (LLTV). METHODS: Plasma nicotine and breath carbon monoxide (CO) concentration and tobacco abstinence symptom severity were measured before and after two 10-puff (30-s interpuff interval) product use bouts separated by 60min. LLTV effects were compared to participants' own brand (OB) cigarettes and an ECIG (3.3V; 1.5ohm; 18mg/ml nicotine). RESULTS: Relative to OB, LLTV increased plasma nicotine concentration to a lesser degree, did not increase CO, and did not appear to reduce abstinence symptoms as effectively. Relative to ECIG, LLTV nicotine and CO delivery and abstinence symptom suppression did not differ. Participants reported that both the LLTV and ECIG were significantly less satisfying than OB. CONCLUSIONS: Results demonstrate that LLTVs are capable of delivering nicotine and suppressing tobacco abstinence symptoms partially; acute effects of these products can be evaluated using existing clinical laboratory methods. Results can inform tobacco product regulation and may be predictive of the extent that these products have the potential to benefit or harm overall public health. Copyright Â
BACKGROUND: Novel tobacco products entering the US market include electronic cigarettes (ECIGs) and products advertised to "heat, not burn" tobacco. There is a growing literature regarding the acute effects of ECIGs. Less is known about "heat, not burn" products. This study's purpose was to expand existing clinical laboratory methods to examine, in cigarette smokers, the acute effects of a "heat, not burn" "loose-leaf tobacco vaporizer" (LLTV). METHODS: Plasma nicotine and breath carbon monoxide (CO) concentration and tobacco abstinence symptom severity were measured before and after two 10-puff (30-s interpuff interval) product use bouts separated by 60min. LLTV effects were compared to participants' own brand (OB) cigarettes and an ECIG (3.3V; 1.5ohm; 18mg/ml nicotine). RESULTS: Relative to OB, LLTV increased plasma nicotine concentration to a lesser degree, did not increase CO, and did not appear to reduce abstinence symptoms as effectively. Relative to ECIG, LLTV nicotine and CO delivery and abstinence symptom suppression did not differ. Participants reported that both the LLTV and ECIG were significantly less satisfying than OB. CONCLUSIONS: Results demonstrate that LLTVs are capable of delivering nicotine and suppressing tobacco abstinence symptoms partially; acute effects of these products can be evaluated using existing clinical laboratory methods. Results can inform tobacco product regulation and may be predictive of the extent that these products have the potential to benefit or harm overall public health. Copyright Â
Authors: Melissa D Blank; Caroline O Cobb; Barbara Kilgalen; Janet Austin; Michael F Weaver; Alan Shihadeh; Thomas Eissenberg Journal: Drug Alcohol Depend Date: 2011-02-01 Impact factor: 4.492
Authors: Stephen S Hecht; Steven G Carmella; Delshanee Kotandeniya; Makenzie E Pillsbury; Menglan Chen; Benjamin W S Ransom; Rachel Isaksson Vogel; Elizabeth Thompson; Sharon E Murphy; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2014-10-21 Impact factor: 4.244
Authors: Caroline O Cobb; Melissa D Blank; Alejandra Morlett; Alan Shihadeh; Ezzat Jaroudi; Nareg Karaoghlanian; Barbara Kilgalen; Janet Austin; Michael F Weaver; Thomas Eissenberg Journal: Nicotine Tob Res Date: 2014-09-25 Impact factor: 4.244
Authors: Alexa A Lopez; Marzena M Hiler; Eric K Soule; Carolina P Ramôa; Nareg V Karaoghlanian; Thokozeni Lipato; Alison B Breland; Alan L Shihadeh; Thomas Eissenberg Journal: Nicotine Tob Res Date: 2015-09-16 Impact factor: 4.244
Authors: Carolina P Ramôa; Marzena M Hiler; Tory R Spindle; Alexa A Lopez; Nareg Karaoghlanian; Thokozeni Lipato; Alison B Breland; Alan Shihadeh; Thomas Eissenberg Journal: Tob Control Date: 2015-08-31 Impact factor: 7.552
Authors: Alison Breland; Eric Soule; Alexa Lopez; Carolina Ramôa; Ahmad El-Hellani; Thomas Eissenberg Journal: Ann N Y Acad Sci Date: 2016-01-15 Impact factor: 5.691
Authors: Alison Breland; Robert L Balster; Caroline Cobb; Pebbles Fagan; Jonathan Foulds; J Randy Koch; Thokozeni Lipato; Najat Saliba; Alan Shihadeh; Shumei Sun; Thomas Eissenberg Journal: Am Psychol Date: 2019-04
Authors: Jenny E Ozga-Hess; Nicholas J Felicione; Stuart G Ferguson; Geri Dino; Daniel Elswick; Catherine Whitworth; Nicholas Turiano; Melissa D Blank Journal: Addict Behav Date: 2019-08-21 Impact factor: 3.913
Authors: Alison Breland; Sarah F Maloney; Eric K Soule; Carolina Ramôa; Andrew Barnes; Thokozeni Lipato; Thomas Eissenberg Journal: Exp Clin Psychopharmacol Date: 2019-07-01 Impact factor: 3.157
Authors: Zongshuan Duan; Daisy Le; Annie C Ciceron; Ruth Dickey-Chasins; Christina N Wysota; Yael Bar-Zeev; Hagai Levine; Lorien C Abroms; Katelyn F Romm; Carla J Berg Journal: Health Educ Res Date: 2022-09-23